Merck's product has been approved in China for the treatment of unresectable non-metastatic hepatocellular carcinoma.

On June 13, Merck announced that its PD-1 inhibitor pembrolizumab has been approved by the China National Medical Products Administration for use in combination with lenvatinib for arterial chemoembolization, for the treatment of inoperable non-metastatic hepatocellular carcinoma patients. This new indication approval is based on data from the Phase III clinical trial LEAP-012.